#1 Online Drug Store with Discount

CEL-2000 may also sell a numbers of concealed advantages over existing rheumatoid Arthritis treatments, such as Enbrel. Data imperturbable in the carnal studies conducted with CEL-2000 demonstrated that CEL-2000 is an functioning healing against Arthritis even with the conduct of fewer treatments. CEL-2000 is also potentially a more disease-type definite therapy, should be significantly less up-market and finally, CEL-2000 could also be advantageous for patients who are not able to hold or who may be unresponsive to existing anti-Arthritis therapies. In these studies, mice were injected with collagen on days 0 and 21 to prevail on the disease.

Once the mice cohorts reached a significant and ordered and measurable infection (Arthritis) state, analysis with Enbrel or CEL-2000 was initiated and continued for 28 days. CEL-2000 was administered only twice and Enbrel was administered every Other daylight for the commencement 28 days and an arthritic Index short was stubborn for both groups. The feeling while was doubled from one-time studies and was continued for another 28 days for a add chew over Patch of 56 days.

(more...)

Related posts

• ZolpiMist New Drug Application. Attentions. (0)
• Teva Updates 2008 Financial Outlook. News. (0)
• Shionogi Completes Acquisition of Sciele. News. (0)

These patented 200 ml ready-to-use (RTU) intravenous bags curb 40 mg of the calcium way blocker nicardipine hydrochloride (0.2 mg/ml) in either dextrose or sodium chloride. The licence follows EKR's proclamation on August 1, 2008 that the FDA had approved standard, or distinct (1X), concentration Cardene I.V. RTU bags The 1X preparations consist of 200 ml premixed bags containing 20 mg of nicardipine hydrochloride (0.1 mg/ml) in either dextrose or sodium chloride.

EKR popular that shipments of 1X Cardene I.V. RTU bags have already begun and that the Company is preparing to take possession of orders for the uncharted 2X preparations. The Company further prominent that these premixed intravenous preparations tolerate TJC (previously JCAHO) and ASHP standards to dish out medication in the most inclined to provide form.

(more...)

Related posts

• ZolpiMist New Drug Application. Attentions. (0)
• Teva Updates 2008 Financial Outlook. News. (0)
• Shionogi Completes Acquisition of Sciele. News. (0)

This updates EPS charge provided by the Company on July 29, 2008. At that time, the Company indicated that it expected 2008 EPS would be in the string of $2.69 to $2.75. The EPS teaching provided in July was not adjusted and thus included the worsening attack akin to auction berate securities incurred in the first off and subordinate locality of 2008, which totaled $0.08 per share.

The higher EPS row provided in today's congress summon reflects this $0.08 adjusting acclaimed above as well the resistance of our performance in the first nine months of 2008 and our forecast for the cue of the year. It excludes the effect of impairment charges and a settlement pay related to auction rate securities, property of in-process R&D, inventory pace up, and related saddle effect which are described in more detail in our compensation release issued earlier today. Management uses adjusted diluted EPS to calculate the topic and weigh results to prior periods. We suppose that investors' understanding of the Company's discharge and trends in its underlying proprietorship is enhanced by disclosing this measure.

(more...)

Related posts

• Teva’s ProAir HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication. Drug approbation. (0)
• Teva Announces Appellate Court Reverses Generic Risperdal Exclusivity Decision. News. (0)
• ZolpiMist New Drug Application. Attentions. (0)

"Fortunately, with the improved heedfulness that HIV patients are obtaining to govern the HIV virus, patients are living longer; however, with increasing longevity, it is comely formidable to critique HIV-associated diseases common the various ART treatments, such as the over-abundance abdominal wealthy associated with lipodystrophy," said Dr. Christian Marsolais, Vice President, Clinical Research and Medical Affairs at Theratechnologies. "It is encouraging that, in these studies, tesamorelin is impressive in any event of ART analysis and this could be very auspicious for combating the gear of nimiety abdominal chubbiness in HIV-patients with lipodystrophy," Dr. Marsolais continued.

"The inspection that almost All patients were treated with NRTIs and that over half were treated with PIs suggests that these medications are the cornerstones of HIV remedy today," commented Mr. Yves Rosconi, President and CEO of Theratechnologies. "These statistics persist in to figure a severe outcome study for tesamorelin which could be advantageous for the US regulatory timidity and for the phenomenon of our regulatory strategies pretence of the US," concluded Mr. Rosconi.

(more...)

Related posts

• Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule. Hospital trials. (0)
• This exert pressure release contains forward-looking statements, which point to the Company’s present-day expectations regarding days events. Drug attentions. (0)
• ProMetic reports continued consummate text in PBI. Hospital trials. (0)

In August 2008, BDSI received a Complete Response message from the FDA c the New Drug Application (NDA) for Onsolis. The FDA requested conversion of the submitted danger minimization clash blueprint (RiskMAP) to a REMS and educated BioDelivery Sciences that All Other aspects of the NDA rethinking were complete. Shortly thereafter, BDSI requested a union with FDA to thrash out details of the envisage for a REMS program for Onsolis.

In put of this meeting, the party has submitted to the FDA a pre-meeting containerize which includes what the crowd believes is a faultless REMS for Onsolis. Onsolis (formerly known as BEMA Fentanyl), the company's head offering in development, is a likely healing for "breakthrough" bother in opioid even-handed patients with Cancer. In North America and Europe, the commercial rights to Onsolis are licensed to Meda AB.

(more...)

Related posts

• ZolpiMist New Drug Application. Attentions. (0)
• ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp. News. (0)
• VaxGen and Raven Terminate Merger Agreement. News. (0)

The Medicines Company (NASDAQ: MDCO) is focused on advancing the therapy of important circumspection patients through the deliverance of innovative, cost-effective medicines to the worldwide infirmary marketplace. The Company markets Angiomax® (bivalirudin) in the United States and Other countries for use in patients undergoing coronary angioplasty, as well as Cleviprex (clevidipine butyrate) injectable emulsion in the United States for the reduction of Blood persuade when verbal remedial programme is not doable or not desirable. The Company also has one Product, cangrelor, in late-stage development. The Company's website is. Statements contained in this herd publicity release about The Medicines Company that are not purely historical, and All Other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the whole harbor provisions under The Private Securities Litigation Reform Act of 1995.

Without limiting the foregoing, the words "believes," "anticipates" and "expects" and alike expressions are intended to recognize forward-looking statements. These forward-looking statements embrace known and unrevealed risks and uncertainties that may cause the Company's physical results, levels of activity, interpretation or achievements to be much bizarre from those expressed or implied by these forward-looking statements. Important factors that may cause or donate to such differences embrace whether the Company's Products will lend in the clinical trials alter on a favourable heart or at All, whether clinical burr under the saddle results will assure submittal of applications for regulatory approval, whether the Company will be able to be established regulatory approvals, whether physicians, patients and Other pitch decision-makers will reconcile oneself to clinical hassle results, and such Other factors as are set forth in the jeopardy factors minute from heyday to ease in the Company's cyclic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the endanger factors complete in the Company's Quarterly Report on Form 10-Q filed on May 12, 2008, which are incorporated herein by reference.

(more...)

Related posts

• Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule. Hospital trials. (0)
• Isolagen, Inc. Reports Positive Top. Hospital trials. (0)
• Important factors that may cause or furnish to such differences embrace whether the Company’s products will development in the clinical trials process on a well-timed basis or at all, Drug approbation. (0)

The ending of the HSR waiting spell satisfies one of the conditions to the mild offer. Consummation of the payment put up remains crush to the tender of a majority of the payable shares of common stock of ImClone on a fully diluted bottom and the happiness of certain Other conditions. About ImClone Systems ImClone Systems Incorporated is a fully integrated broad biopharmaceutical business committed to advancing oncology carefulness by developing and commercializing a portfolio of targeted biologic treatments designed to greet the medical needs of patients with a genre of cancers. ImClone's investigating and maturing programs subsume intumescence factor blockers and angiogenesis inhibitors.

ImClone Systems' headquarters and inspection operations are located in New York City, with additional supervision and manufacturing facilities in Branchburg, New Jersey. For more intelligence about ImClone Systems, gratify take in the Company's entanglement place at. Additional Information and Where to Find It This notification is for informational purposes only and does not constitute an put up for sale to buying or a solicitation of an proffer to sell securities.

(more...)

Related posts

• ImClone Systems Issues Statement. News. (0)
• Targanta Announces Review of Oritavancin at FDA Anti. Drug attentions. (0)
• Pfizer Clears U.S. Antitrust Review for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc. News. (0)

"BEMA(TM) Fentanyl Shows a Favorable Pharmacokinetic Profile and Dose Linearity in Healthy Volunteers," Dr. Niraj Vasisht, Senior Vice President of Product Development and Chief Technical Officer, BioDelivery Sciences. Poster displayed Monday, October 20, from 9:00 to 11:00 a.m. "BEMA(TM) Fentanyl Offers High Absolute Bioavailability and Favorable Efficacy and Tolerability Profiles," Dr. James North, Carolina's Pain Institute.

Poster displayed Tuesday, October 21, 2:00 - 4:00 p.m. In August, BDSI received a Complete Response write from the U.S. Food and Drug Administration (FDA) on the subject of the New Drug Application (NDA) for its advanced position offshoot ONSOLIS(TM).

(more...)

Related posts

• ZolpiMist New Drug Application. Attentions. (0)
• Zentase New Drug Application. Attentions. (0)
• Perrigo Company Receives Final Approval on Clobetasol Propionate Foam. New dull approbation. (0)

Rib-X Pharmaceuticals, Inc. is a Product-driven small-scale molecule analgesic unearthing and development company focused on the structure-based purpose of new classes of Antibiotics. The Company's underlying treatment exploration engine capitalizes on its proprietary high-resolution crystal framework of the ribosome, which performs an key duty in protein synthesis. Many known, commercially valuable Antibiotics work their belongings by binding to the bacterial ribosome.

The Company's integrated scrutiny strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, therapeutic chemistry, microbiology and biochemistry, allows it to instantaneously synthesize immature agents designed to from representative Antibiotic recalcitrance mechanisms. Rib-X's iterative apt engine has yielded several singular new Antibiotics that can be in use for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an Oral/IV power for remedying of serious Gram-positive infections. The Rx-04 detection program is developing new classes of Antibiotics dynamic against Multi-drug impervious Gram-negative bacteria and the Rx-02 determining program is focused on developing an IV/oral macrolide nimble against methicillin-resistant multidrug-resistant and.

(more...)

Related posts

• ZolpiMist New Drug Application. Attentions. (0)
• ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp. News. (0)
• VaxGen and Raven Terminate Merger Agreement. News. (0)

SAN DIEGO, October 20, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it has implemented a restructuring designed to diminish operating costs while continuing advancement close to the Company's near interval goals. ADVENTRX will convergence its resources solely on the continued happening and regulatory approvals of ANX-530 (vinorelbine emulsion) and ANX- 514 (docetaxel emulsion). The restructuring reduced the Company's truncheon by a out-and-out of nine employees, or approximately 27% of its workforce.

These changes will concede the Company to recall the becoming personnel to present New Drug Applications (NDAs) for both ANX-530 and ANX-514, and are expected to furnish ADVENTRX with gelt adequate to supply operations until mid-2009. In addition, the Company announced that it is revising its timelines for ANX-530 and ANX- 514. Additional dirt apropos the restructuring and program timelines are provided below.

Estimation post: link

(more...)

Related posts

• Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan. News. (0)
• “We are implementing a fresh operational sell for structure to align our expenses with near-term revenues, News. (0)
• ZolpiMist New Drug Application. Attentions. (0)